Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

Courvoisier, D S; Alpizar-Rodriguez, D; Gottenberg, J E; Hernandez, M V; Iannone, F; Lie, E; Santos, M J; Pavelka, K; Turesson, C; Mariette, X; Choquette, D; Hetland, M L; Finckh, Axel

doi:10.1016/j.ebiom.2016.08.024

Scientific article

English

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

ContributorsCourvoisier, D S; Alpizar-Rodriguez, D; Gottenberg, J E; Hernandez, M V; Iannone, F; Lie, E; Santos, M J; Pavelka, K; Turesson, C; Mariette, X; Choquette, D; Hetland, M L; Finckh, Axel

Published inEBioMedicine, vol. 11, p. 302-306

Publication date2016

Abstract

Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often heterogeneous. We aimed to identify types of disease activity trajectories following the initiation of a new biologic DMARD (bDMARD).

Keywords

Antirheumatic Agents/therapeutic use
Arthritis
Rheumatoid/diagnosis/drug therapy
Biological Factors/therapeutic use
Biomarkers
Comorbidity
Disease Progression
Female
Follow-Up Studies
Humans
Male
Severity of Illness Index
Treatment Outcome

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Research groups

Citation (ISO format)

COURVOISIER, D S et al. Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study. In: EBioMedicine, 2016, vol. 11, p. 302–306. doi: 10.1016/j.ebiom.2016.08.024

Article (Published version)

CC BY-NC-ND

Identifiers

PID : unige:99162
DOI : 10.1016/j.ebiom.2016.08.024
PMID : 27558858

Journal ISSN2352-3964

485views

200downloads

Creation30/08/2017 15:22:00

First validation30/08/2017 15:22:00

Update time03/02/2025 13:00:44

Status update03/02/2025 13:00:44

Last indexation03/02/2025 13:03:59

Archive ouverte UNIGE

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

Response to disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) is often heterogeneous. We aimed to identify types of disease activity trajectories following the initiation of a new biologic DMARD (bDMARD).

Technical informations